Search published articles


Showing 7 results for Migraine
Efficacy of Cinnarizine and Sodium Valproate in migraine prophylaxis: a clinical trial
M. Togha, M. Rahmat, K. Nilavary, H. Ashrafian, S Razeghi,
Volume 64, Issue 6 (8-2006)
Abstract

Background: Calcium-antagonists (CA) are heterogeneous group of drugs with different efficacy in migraine prophylaxis. Several studies have firmly demonstrated flunarizine (FLU), and verapamil as the proven calcium-antagonists for migraine prophylaxis. Cinnarizine (CIN), is another CA with less complications and less antihistaminic action. There is very few studies to show the effect of this drug on migraine. The current study evaluates the efficacy and safety of cinnarizine on migraine in comparison to sodium valproate, an acceptable drug in migraine prophylaxis.

Methods: The current study is a randomized double blind clinical trial on 133 participants with intractable migraine headache to evaluate the positive effect of cinnarizine in comparison to sodium valproate. The data was collected and analized by SPSS software.

Results: The mean age of cases was 34.3±10 years in Cinnarizine group and 33.4±11 in Sodium Valproate users. The headache frequency decreased to about 50% and its severity to about 30% in both groups. Although the effect of Cinnarizine was started earlier than sodium valproate , there was no significant difference between two groups of cases in improvement of headache attacks. Statistically significant difference was noted in drug’s complication led to discontinuation of treatment, 5.2% in Cinnarizine users in respect to 14% in valproate group.

Conclusion: The patients who received Cinnarizine, similar to the patients on sodium valprote showed significant improvement in headache attacks, frequency, duration and severity. Cinnarizine such as sodium valproate is an effective drug in migraine prophylaxis even in intractable headache, but with lesser severe complication.


Therapeutic effects of acupuncture on patients with migraine: a before-after study
Golbabaii Sh, Ghanbar M, Hemmatpour Kh,
Volume 66, Issue 7 (10-2008)
Abstract

Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 Background: Approximately 2-15% of the global population suffers from migraine headaches. Since acupuncture is one of the treatments for this disorder, the aim of the present study was to assess the effectiveness of this modality on patients with migraine.
Methods: In this experimental interventional study, we enrolled 180 patients with migraine headache attacks at a documented frequency of at least 2 attacks during last 6 months. For all patients, the number, duration and intensity of the headaches were recorded before treatment. To treat the patients, the point with maximal pain was first determined and the meridian was distinguished. Then, the related acupoints were found and stimulated by percutaneous electrical acupuncture for several minutes. The procedure was repeated once per week for six weeks. After completion of all treatment sessions, the patients were visited and questioned about the number, duration and the intensity of headaches.
Results: The mean of number of attacks (9.55±8.26 vs. 3.50±6.77, p=0.001), the mean duration of each attack (9.11±6.59 vs. 3.33±3.65, p=0.001) and the intensity of the attacks (1.83±0.38 vs. 0.61±0.78, p=0.001) were significantly lower after treatment.
Conclusion: Application of acupuncture in patients with migraine headaches is associated with a significant decrease in the mean number, duration and intensity of attacks. Thus, this method of treatment is strongly recommended for migraine headache.


Correlation between migraine headaches and obsessive-compulsive Disorder: a two year study
Ghaleiha Ali, Seyedian Azadeh , Mazdeh Mehrdokht , Seife Rabiee Mehrdokht , Zarabian Mohammad ,
Volume 69, Issue 12 (3-2012)
Abstract

Background: Migraine is the most common cause of headache which affects 15% of female and 6% of male populations. Patients with migraine may have psychological problems, thus, association of migraine with depression, anxiety and other psychological disorders should be considered for choosing the best management approach.

Methods: In this case-control analytical study, one hundred and twenty patients with migraine were recruited among patients who attended the Psychiatry Clinic of Farshchian Hospital in Hamedan, Iran during 2008- 2009. The patients met the IHS criteria for migraine and none had disorders, such as Huntington disease, that are associated with obsessive-compulsive disorder (OCD). The people who accompanied patients attending the Internal Medicine Clinic of the Hospital and had no history of migraine headaches were recruited as the controls. Maudsley's inventory was used for the diagnosis of OCD. Finally, the data were analyzed by SPSS software.

Results: In the control group, 3 (2.5%) and in the case group 11 (9.17%) people had OCD (P=0.024). All of those with OCD in the control group and 9 out of 11 in the case group were female. There were no cases of OCD among patients with mild migraine. Among 36 patients with moderate headache 5 (13.89%) people had OCD and among 62 people with severe migraine 6 (9.68%) had OCD (P=0.510).

Conclusion: The prevalence of OCD in patients with migraine was significantly higher than the normal population. Special attention to comorbid conditions such as OCD is necessary in the management of migraine headaches.


The Relationship between exposure to manganese in welding fumes and incidence of migraine headache symptoms
Younes Mehrifar , Hamideh Pirami , Somayeh Farhang Dehghan ,
Volume 76, Issue 2 (5-2018)
Abstract
Background: Welding generates complex metal aerosols, inhalation of which is linked to adverse health effects among welders. Exposure to manganese (Mn) fume in welding processes can have a harmful effect on welders’ health. Long-term, high-level exposure to Mn is associated with impaired central nervous system (CNS) function. The present study aims to investigate relationship between exposure to manganese in welding fumes and incidence of migraine headache symptoms.
Methods: This cross-sectional analytic study was conducted in March 2017 in an Iron Smelting Industry. Forty welders were selected as the exposure group and thirty-five employees were selected from the administrative unit as the control group. Data related to symptoms of migraine headache were collected using with Ahvaz migraine questionnaire (AMQ). Air samples were collected on mixed cellulose ester membrane filters in personal air samplers and then analyzed using inductively coupled plasma atomic emission spectroscopy (ICP-AES) (NIOSH Method 7300).
Results: The average concentration of welder’s exposure to manganese was 7.24±2.91 mg/m3, which is very higher (37 times) than the occupational exposure limit (Threshold limit value-time-weighted average). There was no significant difference between the mean age and work experience of the two groups (P<0.05). Comparison of the mean of migraine headache symptoms in the two groups of welders and office workers also showed that the frequency of these symptoms among welders was significantly higher than those reported by administrative staff (P<0.05). The correlation between the frequency of symptoms of migraine headache and the concentration of manganese in the air of the welders’ respiratory area was statistically significant (P<0.05).
Conclusion: Frequency of migraine headache symptoms was higher among welders compared to control group. Statistically the significant relationship was found between airborne Manganese concentration and occurrence of migraine headache; however, a conclusive conclusion is based on more comprehensive studies with larger sample size.

The effect of enalapril on pro-inflammatory cytokines in patients with migraine: a double-blind, randomized clinical trial
Shaghayegh Haghjooy Javanmard, Seyed Ali Sonbolestan , Kiyan Heshmat ,
Volume 77, Issue 3 (6-2019)
Abstract
Background: One of the possible mechanisms of migraine pathophysiology is neuro inflammation in which, according to previous studies, some changes happen in inflammatory factors like interleukins, adhesion molecules or acute phase reactants. Cytokines may have an essential role in the neurovascular inflammation and also in the process of pain especially in migraine patients. On the other hand, one of the mechanisms by which angiotensin converting enzyme inhibitors (ACEIs) work is anti-inflammation. The goal of this study was to evaluate the effect of enalapril as an ACEI drug, on the proinflammatory cytokines (calcitonin gene-related peptide (CGRP), tumor necrosis factor alpha (TNFα)) of migraine patients.
Methods: In this randomized double blind placebo-controlled clinical trial, 40 migraine without aura patients (mean age of 34.42±1.82 years) who were referred to neurology clinics of Isfahan University of Medical Sciences, Iran, between June 2011 and July 2012 were recruited. The patients were randomly divided into two groups. 21 patients were treated with 10 mg enalapril daily for two months as the intervention group and they were compared with matched placebo treated group of 19 patients. Serum samples were collected from all of the subjects and TNFα and CGRP levels were measured by means of ELISA (enzyme-linked immunosorbent assay) kits at the beginning of study (before the intervention) and after 2 months of enalapril or placebo treatment. The serum levels were compared in each group and between the groups. SPSS software, version 16 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
Results: Six males (15%) and 34 females (85%) were enrolled in this study. The mean of migraine history among the subjects was 74.40±7.54 months. Patients' TNFα level decreased significantly in the case group after treatment with enalapril (P=0.001) while there was no significant change in control group (P=0.769). There was no significant difference in the CGRP concentrations in the intervention and control groups (P=0.795, 0.708 respectively).
Conclusion: Enalapril may be effective in improvement of inflammatory responses of migraine patients by decreasing the inflammatory factors like TNFα.

A comparative study of the efficacy of coenzyme Q10 and propranolol in prophylaxis of migraine headaches: a double-blinded clinical trial
Hadi Gharebaghian, Azar Ghasemi , Elaheh Hoseinpour,
Volume 80, Issue 9 (12-2022)
Abstract

Background: Migraine is a recurrent disease which its definitive mechanism is still unknown. Thus mitochondrial dysfunction and neurovascular damage are two hypothetical underlying mechanisms for migraine headaches. The effectiveness of some possibly effective compounds such a CoQ10 has been studied. In this study, we evaluated the efficacy of coenzyme Q10 in migraine headache prophylaxis.
Methods: This study was performed as a double-blinded randomized clinical trial on 112 patients with a diagnosis of migraine who were referred to the Neurology Clinic of Imam Reza Hospital in Kermanshah from March to September 2018. Then the patients were randomly divided into two equal groups (control and intervention). Both groups received propranolol 20 mg twice daily (totally 40 mg/d). The intervention group was treated by CoQ10 60 mg once daily, additionally. Finally, the quantitative and qualitative characteristics of migraine headaches such as nausea and vomiting, photophobia, phonophobia, severity, frequency and duration of attacks were evaluated by Student's t-test, Mann-Whitney U test and Wilcoxon tests.
Results: At the end, it was concluded that CoQ10 supplement of 60 mg daily with propranolol 40 mg daily in patients with migraine headaches improves symptoms more than receiving propranolol 40 mg alone. The results also showed that in the intervention group, nausea and vomiting, photophobia and the severity of headache in patients significantly improved compared to the control group (P values of 0.001, 0.114 and 0.001, respectively). However, the symptoms of phonophobia, frequency and duration of headache attack in the intervention group were not significantly different from the control group (P values were 0.062, 0.853 and 0.106, respectively).
Conclusion: In conclusion considering the main goal of this study, consumption of CoQ10 60 mg daily with propranolol 40 mg daily significantly improves symptoms such as nausea and vomiting, photophobia and severe headache compared to propranolol 40 mg daily. In conclusion, CoQ10 is a suitable choice in patients who do not respond adequately to the standard drug regimen.


Investigating the effectiveness of Sodae herbal capsule on migraine headaches and comparing it with sodium valproate
Daryoush Afshari, Mansour Rezaei, Mojtaba Khazaei, Negin Fakhri ,
Volume 81, Issue 12 (2-2024)
Abstract
Background: One of the first-line treatments to prevent migraine attacks is Sodium Valproate. "Booali Daroo" pharmaceutical company has made a herbal capsule called Sodae based on traditional Iranian medicine. The aim of this study is to compare the effect of Sodae and Sodium Valproate on migraine headaches.
Methods: This two-center, double-blind, randomized clinical trial was conducted between December 2021 and July 2022 in the cities of Kermanshah and Hamadan. In this study, 76 migraine patients were randomly divided into two groups. One group received routine medication with Soda capsules and the other group received routine medication with Valproate capsules. Tow group were examined and followed up for three months. Data related to demographic and clinical information of patients were collected and entered into SPSS software version 25. Data analysis was done with a significance level of 0.05.
Results: Overall, 76 patients assessed (36 in the Sodae group and 40 in the Valproate group). The reduction of headache indicators was not significant between the two groups; in such a way that: the frequency (7.49±6.1 vs. 5.75±4.5, P=0.183), the severity (5.66±1.6 vs. 6.34±1.8, P=0.089), the duration of attacks (23.48±30.5 vs. 32.35±32.6, P=0.069), and the Migraine Disability Assessment Score (53.94±77.3 vs. 95.94±104.2, P=0.061) respectively in Valproate and Sodae. Examining different classes of MIDAS score showed that at the end of the study compared to the beginning of the study, the number of people with severe disability decreased significantly and their disability changed from severe disability to lower degrees of disability (P<0.05). The frequency of side effects was not significantly different between the two groups (12 patients (35%) in Sodae versus 21 patients (55%) in Valproate, P=0.090).
Conclusion: In terms of frequency, intensity and duration of migraine headaches as well as side effects, there was no significant difference between Sodium Valproate and Sodae groups.

Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb